By 
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.
The pharmaceutical company
AZN,
-0.15%
said Enhertu has been recommended by the EU’s Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
Comments